The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention-Reference-Cited by-同舟云学术

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention

Published:2009-08 Issue:8 Volume:54 Page:678-685
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

O'Donoghue Michelle,Antman Elliott M.,Braunwald Eugene,Murphy Sabina A.,Steg P. Gabriel,Finkelstein Ariel,Penny William F.,Fridrich Viliam,McCabe Carolyn H.,Sabatine Marc S.,Wiviott Stephen D.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans;Asai;Platelets,2006

2. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease;Jernberg;Eur Heart J,2006

3. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation;Brandt;Am Heart J,2007

4. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood;Storey;Platelets,2001

5. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction;Biomedicines;2024-09-04

2. Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study;European Heart Journal - Cardiovascular Pharmacotherapy;2024-04-11

3. In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors;Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology;2022-07-13

4. Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention;Journal of Cardiovascular Pharmacology;2022-07

5. Antiplatelet agents for chronic kidney disease;Cochrane Database of Systematic Reviews;2022-02-28